Journal
BIOMARKERS
Volume 18, Issue 8, Pages 679-686Publisher
INFORMA HEALTHCARE
DOI: 10.3109/1354750X.2013.845610
Keywords
Early diagnosis; exhaled breath condensate; microRNA; non-small-cell lung cancer
Categories
Funding
- Emilia Romagna Region, Research Program Region-University, Early Molecular Diagnosis of Lung Cancer
Ask authors/readers for more resources
Lung cancer is a major cause of death in Western countries. Current screening methods are invasive and still lead to a high percentage of false positives. There is, therefore, a need to find biomarkers that increase the probability of detecting lung cancer early. MicroRNAs (miRNAs) are stable molecules in blood plasma and exhaled breath condensate (EBC). We quantified miRNA-21 and miRNA-486 expression from plasma and EBC samples from patients with a diagnosis of non-small-cell lung cancer (NSCLC) and controls. miRNA-21 was significantly higher in plasma and in EBC of the NSCLC patients and miRNA-486 was significantly lower. This difference indicates a significantly improved diagnostic value, and suggests that these miRNAs could be clinically used as a first-line screening test in high-risk subjects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available